
Anebulo Pharmaceuticals Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Anebulo Pharmaceuticals Inc
Access all reports
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for acute cannabinoid intoxication (ACI) and substance abuse. Its primary product candidate, ANEB-001, is a cannabinoid receptor antagonist aimed at rapidly reversing the effects of cannabinoid overdose. The company is headquartered in Lakeway, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
ANEB
Country
🇺🇸 United States